STAT August 11, 2022
Damian Garde and Allison DeAngelis and Adam Feuerstein

Are biotech’s fortunes finally changing? Is Big Science impeding actual science? And what will Medicare negotiation mean for drug prices?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. STAT’s Jason Mast joins us to discuss Jim Wilson, a pioneering scientist synonymous with the rise of gene therapy who staffers say presided over a toxic, abusive workplace. We also explain the latest news in the life sciences, including a multibillion-dollar deal, a novel approach to treating schizophrenia, and what the Senate drug pricing legislation means for the pharmaceutical industry.

For...

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

 
Topics: Biotechnology, Conferences / Podcast, Insurance, Medicare, Pharma / Biotech, Trends
STAT+: After AI protein folding, David Baker’s lab identifies millions of smaller drug candidates
Fierce Biotech Layoff Tracker 2024: BMS to cut 2K+ roles; Tessera trims workforce in shift to clinic
What Do Weight-Loss Drugs Mean for Diet Industry Built on Eating Less and Exercise?
Podcast #1: Doing Digital Deals in Life Sciences | Corporate Culture
BMS plans $1.5B in cuts through '25, with 2000-plus layoffs

Share This Article